B cells baffle T cells
Monday, 19 January, 2009
Sydney researchers investigating the role of the cytokine known as BAFF have found that while it has a normal pro-inflammatory function, it also has a surprising role in regulating T cell response, in an anti-inflammatory manner.
BAFF (B cell activation of the TNF family) is considered to be primarily involved in B cell activation, as its name suggests, but previous studies have shown that it may also be involved in the regulation of T cell response.
In vitro studies have shown that higher levels of BAFF co-stimulates both human and mouse T cells, and in vivo studies have shown that BAFF-transgenic mice display exaggerated T-dependent antigen responses.
It has also been observed that loss of BAFF signalling impairs the development of antigen-specific T cell responses.
All of this data shows that BAFF has a pro-inflammatory role with regard to T cells.
Now, however, researchers led by PhD student Stacey Walters and Dr Shane Grey of the Garvan Institute in Sydney have found that when BAFF is over-expressed, it has also has an anti-inflammatory role, with effector T cells unable to do their duty.
In fact, in BAFF transgenic mice, T cell effector responses were profoundly compromised, to the extent of accepting tissue allografts.
The reason behind this is that increased levels of BAFF expands the number of CD4+ Foxp3+ regulatory T cells, which are known to inhibit immune responses. It was not thought previously that B cells had a role in T regulatory cells, but this study, the researchers say, shows that BAFF has a complex, dichotomous role to play in immunity.
The work is published in the Journal of Immunology.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
